Meeting
2024 ASCO Genitourinary Cancers Symposium
Neoadjuvant pembrolizumab (PEMBRO) and axitinib (AXI) in renal cell carcinoma with associated inferior vena cava tumor thrombus (NEOPAX).
Authors
Stephanie Lakritz
University of Colorado, Denver, CO
Stephanie Lakritz , Nellowe Candelario , Andrew Nicklawsky , Simon P. Kim , Elizabeth R. Kessler
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT05969496
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr TPS488)
DOI
10.1200/JCO.2024.42.4_suppl.TPS488
Abstract #
TPS488
Poster Bd #
M9
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Quality Care Symposium
Uptake and efficacy of immuno-oncology combinations in metastatic renal cell carcinoma in the United States: Evidence from the ASCO CancerLinQ Discovery database.
First Author: Joseph Vento
Poster
2023 ASCO Genitourinary Cancers Symposium
The survival outcomes of metastatic non-clear cell renal cell carcinoma in the immunotherapy era: Princess Margaret Cancer Centre (PMCC) experience.
First Author: Esmail Mutahar Al-Ezzi
Poster
2021 ASCO Annual Meeting
Efficacy outcomes of nivolumab + cabozantinib versus pembrolizumab + axitinib in patients with advanced renal cell carcinoma (aRCC): Matching-adjusted indirect comparison (MAIC).
First Author: Bradley Alexander McGregor
Poster
2021 Genitourinary Cancers Symposium
Outcomes for patients in the pembrolizumab+axitinib arm with advanced renal cell carcinoma (RCC) who completed two years of treatment in the phase III KEYNOTE-426 study.
First Author: Elizabeth R. Plimack